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 Estrogens are steroid hormones produced by the ovaries and extra ovarian tissues 
including the adrenal gland and adipose tissue. There are 3 major physiologically relevant 
estrogens in the human body, the most potent and biologically relevant of which is 17b-estradiol 
(E2). E2 exerts its physiologic functions by acting through two isoforms of Estrogen Receptor 
(ER); ERa and ERb. ERs are normally bound to heat shock chaperone proteins but once E2 
diffuses across the cell membrane and binds to the ligand binding pocket of ER it sheds these 
proteins, homodimerizes and binds to DNA recruiting transcriptional machinery and 
upregulating a number of target genes including those important for proliferation. Estrogens 
acting through ERa play a central role in the proliferation of breast and ovarian cancer cells as 
evidenced by the mainstay clinical adjuvant therapies for breast cancer which target the ligand 
pocket of estrogen receptor by either competitively displacing endogenous ligand, or by 
inhibiting the rate dependent enzymes responsible for synthesizing the endogenous ligand.  
 While the importance of E2-ERa as a central regulator in breast cancer proliferation is 
unquestioned, it remains unclear how ERa is activated when the clear majority of women who 
develop breast cancer are post-menopausal. After menopause the concentrations of E2 are at their 
lowest point in a woman’s life. Epidemiologic studies show that the level of E2 necessary to 
increase the risk of breast cancer in a post-menopausal woman is in the picomolar range. 
However, the known binding affinity of E2 for ERa lies between 0.5 and 2 nM. It was not known 
whether E2 concentrations in the picomolar range can exert biological effects on cell 
proliferation and gene expression. Moreover, the identity of key regulators of E2-ERa induced 
proliferation are not fully characterized. Recent reports indicate that roughly 15% of the human 
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genome is regulated by Estrogen Receptor. This growing list of ER regulated genes has been 
compiled, but determining which genes are critical factors in E2 induced proliferation has 
remained challenging.    
 In order to probe these questions, we developed techniques for studying the effect of low 
concentrations of E2 on estrogen induced cell proliferation and gene expression. We used this 
information to begin to identify critical ERa regulated genes. Moreover, we developed a new 
experimental model that allows us to identify genes critical for E2-ERa dependent cell 
proliferation in a nearly isogenic cell system.    
 Through careful removal of exogenous estrogens we have developed a cell culture system 
in which the growth of ERa positive cell lines is solely dependent on the addition of E2 to the 
system. Therefore, in this system E2 is the missing factor preventing the cells from proliferating. 
Using this model we found that picomolar concentrations of E2 are able to stimulate near 
maximal proliferation of MCF-7, T47D, T47D ERa D538G, BG1 and PEO4 breast and ovarian 
cancer cells. Furthermore, picomolar E2 stimulates robust colony formation in anchorage 
independent soft agar assays. This effect is not primarily mediated through ERa’s extra-nuclear 
activation of the ERK signaling pathway, but rather through ERa’s classic nuclear mechanism of 
action. Utilizing qPCR we analyzed expression of a number of genes and find that some genes 
are concordantly regulated at picomolar and nanomolar concentrations while other genes, such as 
FOS, were regulated by nanomolar but not picomolar concentrations of E2. Finally, we show that 
picomolar concentrations of E2 are sufficient to elicit robust recruitment of ERa to regulatory 
elements in estrogen responsive genes.  
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 The second tool described in this work is a set of nearly isogenic cell lines with a specific 
phenotypic difference. The T47D KBluc cell line was originally developed as a breast cancer cell 
line stably transfected with a (ERE)3-luciferase reporter in order to detect environmental 
estrogens. A key difference between this cell line and its parental T47D cell line is that E2 does 
not stimulate proliferation of the cells. We demonstrate that this cell line contains ERa, that the 
ERa is functional and able to regulate both the transfected reporter and endogenous genes. We 
also tested a panel of known ERa regulated genes to see if any of the genes are discordantly 
regulated between the two cell lines; this would suggest the gene might play a role in E2 induced 
cell proliferation.  
 These two tools represent an important step in furthering our understanding of E2-ERa 
regulated cell proliferation. Notably, we show experimentally that the extremely low 
concentrations of estrogen identified as tumorigenic in epidemiological studies are sufficient to 
induce growth of breast cancer cells in the laboratory. This work demonstrates the potential of a 
novel approach to pursuing genome wide transcriptome studies of ERa action in order to 
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Chapter One 
Background and Significance 
 
1.1 Estrogen concentrations and breast cancer risk 
The link between estrogen production and breast cancer has been evident ever since 
George Beatson described oophorectomy as a treatment for breast cancer in an 1896 edition of 
the Lancet[1]. Since then the association between early menarche and lifetime estrogen exposure 
has become well established[2]. However, it is only with more precise measurement and large 
epidemiological studies that our understanding of postmenopausal hormone levels and the risk of 
developing cancer has been described. 
A 2002 JAMA article demonstrated that the risk of developing breast cancer in post-
menopausal women increased 6.9 fold if their serum E2 levels were greater than 10 pM[3]. A 
number of more recent articles, while not achieving the same figure, have shown that the serum 
E2 levels necessary to increase the risk of breast cancer lie in the low picomolar range[4-7]. This 
increase in relative risk is despite the fact that the Kd of estrogen receptor is known to be 0.5-2 
nM, demonstrating a significant disparity between the known binding affinity of ERα for E2 and 
serum E2 levels[8, 9].  
While the links between circulating post-menopausal hormone levels and the risk of 
developing breast cancer are well described from an epidemiological standpoint, it is unclear 
whether these hormones levels have measureable biological effects[5]. In fact, it has always been 
assumed that picomolar concentrations of E2 were too low to induce gene transcription, 
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translation of proteins, or carrying out other biological functions in breast cancer cells as well as 
normal tissues due to the discrepancy between binding affinity and circulating concentrations. In 
the remainder of this chapter we explore the production of estrogens in relation to normal 
physiology, its actions through estrogen receptor, its function in breast cancer, as well as its 
importance as a therapeutic target. 
1.2 Estrogen synthesis and transport 
Estrogens are a group of steroid hormones derived from cholesterol that are produced by 
various tissues in the human body including the ovaries, adrenal glands, and adipose tissue (Fig 
1.1)[10]. Estrogens, as a general class of steroid hormone, are the endogenous ligands for both 
the a and b isoforms of estrogen receptors with Estrogen Receptor a (ERa) being the major 
mediator in breast cancers. There are three endogenous estrogens; 17β-estradiol (E2), estrone 
(E1) and estriol which have physiologically relevant effects [11-13] However, the hormone with 
the highest binding affinity for ERα and the greatest biological significance, especially related to 
breast cancer, is 17β-estradiol (E2)[8] .  
During the ovulatory years of a woman’s life estrogen production in the human body is a 
highly regulated endocrine process requiring multiple levels of signaling. This system requires 
the hypothalamus, pituitary, and gonads to function in concert to produce estrogens. The ovaries 
are the major site of Estradiol production in the pre-menopausal woman.  The two-cell theory for 
estrogen production as outlined in Figure 1.2 illustrates the basic mechanism of action[14]. 
GnRH in the hypothalamus is released in to the hypothalamic portal system where it acts on the 
posterior pituitary to stimulate the secretion of Luteinizing Hormone (LH) and Follicle 
Stimulating Hormone (FSH) from gonadotropes in the pituitary. From the pituitary LH and FSH 
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travel via the blood to act on the ovaries. Two distinct cell types within the ovarian follicle 
epithelium participate in the coordinated production of 17β-estradiol; theca cells and granulosa 
cells. Theca cells are acted upon by LH through the Luteinizing Hormone Receptor to promote 
the conversion of cholesterol via a multistep pathway to androstenedione.  
As a hydrophobic steroid hormone, androstenedione can diffuse through cell membranes 
in to the neighboring granulosa cells where the androstenedione is converted to estrone (E1). 
This takes place through a member of the cytochrome P450 family of enzymes CYP19A1, a 
monoxygenase, also known as aromatase. The activity of aromatase is regulated by FSH acting 
via the FSH receptor on granulosa cells. A second enzyme 17 Beta hydroxysteroid 
dehydrogenase (17b HSD1) reduces estrone (E1) to estradiol (E2). From the ovaries E2 is able to 
diffuse across cell membranes and travel within the blood predominantly bound to albumin and 
sex hormone binding globulin (SHBG) while less than 2% remains unbound. From the blood 
estradiol can exert its effects on many tissues including the uterus, breast, bone, and brain [12-
17].  
The site and amount of estrogen production, particularly estradiol, varies from the 
premenopausal state to the postmenopausal state.  As outlined above, estrogen production in the 
premenopausal woman takes place primarily in the ovaries. However, during menopause ovarian 
senescence eventually leads to amenorrhea and a significant decrease in gonadal estrogen 
production. Consequently, in the post-menopausal woman the majority of estrogen production 
takes place in extra ovarian tissue such as the adrenal cortex[18]. The major estrogen secreted by 
the adrenal cortex is in the form of estrone which can be converted by aromatase in peripheral 
adipose tissue to estradiol[13, 19]. Therefore, the circulating levels of E2 tend to be higher in 
obese individuals with large amounts of adipose tissue than those who do not have an elevated 
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BMI [20-23]. However, the result is a precipitous decline in overall estrogen production as well 
as  a drop in E2 production due to the lack of conversion of E1 to E2 [15, 16, 24] . Figure 1.3 
diagrams variation in E2 levels over a woman’s lifetime[25]. The figure illustrates that E2 levels 
increase from puberty, peak during menstrual cycle and drop to some of the lowest points during 
menopause. Estimates vary regarding the differences in circulating concentration before and after 
menopause. However, there is general agreement that circulating concentrations of E2 drop from 
peak ovulatory levels in the nanomolar range to the picomolar range[4, 6, 7, 26]. Best estimates 
place the lowest levels of estradiol during normal menstrual cycle at approximately 200 pM 
while the highest circulating levels are approximately 1500 pM. After menopause the circulating 
levels of estradiol have a wide range of estimates from 1-15 pM [27].   
1.3 ERα structure and action 
Estrogen Receptor (ER) is a Class I member of the nuclear receptor superfamily that 
binds and is activated by the endogenous ligand 17β-estradiol (E2).  In the human body there are 
two isoforms of Estrogen Receptor, a and b, which are encoded by ESR1 and ESR2 on distinct 
chromosomes. While both isoforms are expressed in a wide variety of tissues and are important 
physiologically, ERa is more directly implicated in oncogenesis. Structurally ERα has 12 a 
helices and a number of characterized functional domains (Figure 1.4) that contribute to its 
actions. Notably it has a ligand binding domain, a DNA binding domain (DBD), and 2 activation 
function domains (AF 1 and AF2)[28-30].  
 Classically, ER function is described as regulating the transcription of genes via 
interactions with DNA. The majority of ERa is found in the nucleus bound to stabilizing heat 
shock proteins such as HSP90. Binding of E2 to ERα releases E2 -ER complex from stabilizing 
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proteins and allows the activated receptor to homodizmerize[31]. Activation and 
homodimerization allows ER to bind via zinc fingers in the DBD to DNA sequences called 
Estrogen Response Elements (EREs) found either at the promoter or at distant sites several 
thousand base pairs away called enhancers (Fig 1.5)[32]. Once bound to DNA ER can recruit co-
activators and co-repressors through the activation function domains to assemble a transcription 
complex and regulate the transcription of target genes. Specifically, helix 12 appears to be of 
critical importance to transcriptional regulation through the recruitment of co-activators, such as 
the p160 family of proteins or co-repressors including NcoR and SMRT which utilize an LXXLL 
motif. Alternatively, the receptor can induce transcription of genes through tethering 
mechanisms that do not require direct interaction of the E2 •ER complex with DNA at AP-1, SP-
1, RUNX1 and FOXA1 binding sites [33-36] . 
The classical mechanism description of ER action revolves around its originally 
recognized role as a transcription factor. However, in recent years alternate mechanisms of ERα 
action have gained broad acceptance. The most prominent and best studied to date is non-
genomic ERα signaling, where membrane bound receptor activates rapid signaling pathways 
such as MAP kinase and Akt. Since ERα does not have a catalytic domain, the activation of these 
signaling cascades relies on the formation of multiprotein complexes around ERα resulting in the 
activation of signaling cascades [37, 38].  
Another mechanism of action proposed for estrogens is via a unique orphan G Protein 
Coupled Receptor (GPCR) named GPR30. GPR30 is a GPCR that has been reported to bind E2 
with high affinity[39-41]. GPR30 has been reported to function by activating intracellular 
signaling mechanisms including cAMP and the kinase PKA resulting in the regulation of ion 
channels and fluxes in intracellular or intraluminal calcium[42, 43]. However, the 
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characterization of GPR30 is not without a number of conflicting reports including the relative 
concentrations necessary to activate the receptor which have been reported as greater than 1 uM; 
reports that very high concentrations anti estrogens such as 4-OHT and Fulvestrant activate the 
receptor; that anti-estrogens have been reported to increase the proliferation of breast cancer 
cells; and even the subcellular localization of the receptor [44, 45] 
Recently, the importance of ERa in regulating the rate of protein synthesis by activating 
the Unfolded Protein Response (UPR) has been reported[46]. As part of the process for initiating 
proliferation of breast cancer cells the endoplasmic reticulum must balance the synthesis of new 
proteins with the availability of chaperones which is directed by the UPR. Recent studies have 
revealed that ERa is able to regulate this pathway via activation of PLCg which causes a calcium 
efflux from endoplasmic reticulum resulting in a temporary halt to translation via the 
phosphorylation of eIF2a and readying of the chaperones via the remaining two arms of the UPR 
for correct protein folding [46-50].  
Estrogens, most importantly E2, operate via several pathways to regulate the proliferation 
of cells. These pathways utilize ERa primarily to regulate gene transcription and cell 
proliferation.  
1.4 The estrogen transcriptome and key players 
A key question in the estrogen receptor field has been the identity of the genes ERα 
regulates. Identification of ERα regulated genes has proved exceedingly difficult since ERα 
binding sites have diverse sequences and, through enhancer elements, can be thousands of base 
pairs away from the gene they regulate[51, 52]. Also, indirect ER interaction with DNA through 
protein-protein tethering mechanisms make the identification of genes difficult. Recent papers 
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have suggested that as much of 15% of the global transcriptome could be regulated by E2 
through ERα[53].  While the global regulation of a significant portion of the genome through the 
E2-ERa complex is true at hormone concentrations several fold higher than is seen at ovulation it 
is unknown whether these effects are evident at the lower physiologic concentrations observed in 
post-menopausal women.  
It is known that ERα regulates a number of putative cell cycle genes important in the 
proliferation of breast cancer cells including E2F1, c-fos, and c-myc[54-58]. ERa also has a role 
in inhibiting apoptosis through factors such as BCL-2 and BCL-XL[34, 59]. However, the list of 
genes tested spans tens of genes and distinguishing between key players regulated by E2-ERa 
through direct transcriptional mechanisms and secondary actors not directly regulated by 
estrogen receptor has been difficult.  
1.5 Estrogens and estrogen receptor in normal physiology 
 In non-pathologic physiology E2 and ERa have important roles to the growth and 
development of a wide variety of tissues in both men and women. These tissues include but are 
not limited to brain, bone, breast, uterus, and cardiovascular systems [11, 13, 15, 17]. Below we 
shall briefly discuss a few tissues in which the importance of E2-ERa have been well established. 
 Bone is a tissue in which estrogens have been shown to play an important role even 
though only a few hundred molecules of ERa are present in a given bone cell[60-62]. In bone 
estrogens such as E2 modulate the closure of epiphyseal plates, bone maturation and, most 
importantly, bone resorption[17]. Estrogen has been shown to modulate osteoclast and osteoblast 
activity. This apparent through pathologic conditions such as osteoporosis where one of the 
mainstay treatments for women is raloxifene, an estrogen receptor modulator[63, 64]. 
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 E2-ERa’s role in the cardiovascular system is complex owing to the number of factors 
that influence cardiovascular health including lipid metabolism, hypertension, diabetes and other 
comorbid conditions. Much of what is concluded about the influence of estrogens is based on 
large scale epidemiological data with correlation through animal models. E2 influences lipid 
metabolism through the liver. Estrogen increases HDL and lowers LDL which are markers for 
cardiovascular disease. Evidence suggests that E2 has a protective role in cardiovascular health as 
evidenced by the increase in stroke and myocardial infarction after surgical or physiologic 
menopause. While the Women’s Health Initiative Study (WHI) could not demonstrate a decrease 
in cardiovascular disease with Hormone Replacement Therapy there were indications within the 
study group that HRT at the onset of menopause may be related to lower CVD risk. However, 
subsequent studies analyzing this timing hypothesis have been unable to prove a beneficial effect 
of early initiation of HRT [65].   
Estrogen exerts its influence on breast development at puberty during a period known as 
thelarche which is usually between the ages of 8-13[66]. Breast tissue is made up of between 12-
20 conical lobes each of which consists of a group of lobules that contain lactiferous ducts. At 
puberty, in response to E2 stimulation, breast tissue starts to enlarge owing to an increase in 
acinar tissue, ductal epithelial proliferation, and subsequent increases in amount of adipose 
tissue. While E2-ERa interactions are important to the normal growth and development of breast 
tissue, later in life pathologic mutations in the breast epithelium contribute to breast cancers in 




1.6 Importance of ERα in breast cancer 
Breast cancer is defined as a carcinoma normally found through the clinical presence of a 
firm immobile mass in the breast tissue or, in the United States and other developed countries, 
through routine screening mammography[65].  Breast cancer is the third leading cause of cancer 
deaths in the United States. Approximately 225,000 women per year will develop breast cancer 
and almost 40,000 women will die, meaning that about 1 in 8 women will be diagnosed over 
their lifetime[67, 68]. Men are also at risk of developing breast cancer but they account for less 
than 1% of all cases[67]. The risk of developing breast cancer rises with age and increases 
dramatically after age 50. The risk of developing breast cancer at 40 is approximately 1: 250 and 
rises to 1:50 by age 50[17].  
Most breast cancers (>95%) arise from the breast epithelium. Clinically the diagnosis of 
breast cancer must be made from histologic makeup of the cells derived from a biopsy of the 
mass. However, once a histologic diagnosis has been made based on the sample architecture and 
cell morphology, molecular diagnostics can be used to further subdivide the breast cancers and 
provide information on prognosis and treatment. Receptor testing for the presence of ER and PR, 
defined as positive immunohistochemistry >1% of the histologic sample, is a mainstay of 
classifying prognosis and treatment. In a sample of 61,309 cases of breast cancer roughly 80% 
were ER+ and/or PR+, 23% were HER2+, while 13% were negative for all three [69]. Therefore, 
ERα+ breast cancer is the most prevalent type of breast cancer, accounting for nearly 70% of the 
diagnosed breast cancer cases with increased incidence due to age[70, 71]. 
Once a diagnosis has been established surgical excision of the cancer via either a 
lumpectomy, removal of the local tumor tissue along with a margin for healthy tissue, or 
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modified radical mastectomy are undertaken [72, 73]. Adjuvant therapy added on to the 
treatment regimen after surgery can also be undertaken. This could consist of chemotherapy 
regimens, radiotherapies, or endocrine therapies [74]. The decision of which treatment regimen 
to follow relies on immunohistochemical analysis of the sample.  In the case of breast cancer, the 
presence of the hormone receptors ER and PR predicts the response to endocrine therapies which 
target either estrogen receptor or the ligand 17b estradiol.  The degree of endocrine therapy 
benefit is directly related to the level of ERa expression within the tumors. A meta-analysis of 
the Early Breast Cancer Trialists Collaborative Group showed the response to adjuvant therapy 
with tamoxifen reduced the recurrence by 39% and death by 30% in 15 year follow up[75].  
Besides the information provided by histology and immunohistochemical studies 
molecular information also provides information on prognosis. Staging of breast cancer based on 
tumor burden and the presence of distant metastasis provides the best information on prognosis 
but molecular information based on gene expression profiles from biopsy samples can provide a 
wealth of information. The three major molecular subtypes are luminal, Human Epidermal 
Growth Factor Receptor 2 (HER2) enriched, and basal subtypes.  Luminal A and B subtypes are 
characterized by similarity in gene expression between the cancer and the luminal epithelium 
[59, 69, 76-81]. Luminal A have high expression of ER related genes, low expression of HER2, 
and low expression of proliferation related genes. Luminal B have lower expression of ER 
related genes and high expression of proliferation related genes. The HER2 overexpress a type of 
human epidermal growth factor receptor which has a targeted therapy called Herceptin. Basal 
subtypes, named for the gene expression similar to basal epithelial cells, are ER negative and 
generally fall under the category of “triple negative” breast cancers. Triple negative cancers have 
a poor prognosis.  
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The importance of estrogen receptor in breast cancer is evidenced by the success of 
therapies that target it.  Mainstay adjuvant therapies for ERα+ breast cancer target the receptor 
via 2 broad modes of action. The first involves inhibiting the aromatase enzyme thereby 
suppressing E2 production and depriving ER of its endogenous ligand. The second method 
involves blocking the binding of E2 to ERα by utilizing competitive inhibitors. Tamoxifen a 
Selective Estrogen Receptor Modulators (SERMs) and Fulvestrant a Selective Estrogen Receptor 
Degraders (SERDs) compete with E2 for the Ligand Binding Domain (LBD) of ER[29, 82, 83].  
1.7 Endocrine therapies in the treatment of breast cancer 
 ERa is an important therapeutic target in breast cancer as evidenced by the number of 
tumors that express the receptor, the receptors’ role in promoting proliferation and tumorgenesis, 
as well as its clinical importance in the prognosis of breast cancer. There are two major 
therapeutic approaches to targeting estrogen receptor. The first is to target ERa via its classical 
mechanisms of gene transcription through pure or partial antagonism of the receptor by 
displacing the endogenous ligand.  The second is to target E2 the ligand that binds and activates 
ERa by decreasing its production from ovarian or extra ovarian tissue.  
 One of the most successful medications in the treatment of breast cancer over the last 50 
years has been the SERM tamoxifen. Tamoxifen is structurally similar to estrogen, as seen in 
Figure 1.6 [20]. Tamoxifen is able to block the functions of estrogen receptor in breast tissue by 
binding to the ligand binding pocket and displacing helix 12. Helix 12 normally functions to 
recruit co-activators but its displacement blocks the interaction surface for coactivators[84, 85]. 
While tamoxifen acts as an antagonist in the breast, it functions as a partial agonist in bone, 
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endometrial, and cardiovascular tissue presumably because of difference in coactivator 
expression within these tissues[29].  
Another type of competitive inhibitor which is considered a third line endocrine therapy 
is called ICI 182 780, also known by the trade name Fulvestrant or Faslodex[82]. Unlike 
tamoxifen, ICI is not a SERM but a SERD which does not have any partial agonist activity and 
functions as a pure antagonist. Fulvestrant is also similar in structure to endogenous estrogens 
(Figure 1.6)[20]. It functions by binding to the ligand binding pocket but induces degradation of 
the protein through the 26s proteasome [82]. Two major drawbacks to the clinical utility of 
Fulvestrant are reports that it can take up to 6 months to reach therapeutic levels in the blood as 
well as the fact that for long term therapy tissue specific antagonism is preferable due to the 
beneficial effects of estrogen on the bone and brain [63, 64]. 
A second category of clinically important therapies are aromatase inhibitors (AIs) [86]. 
Aromatase is the rate limiting enzyme in the biosynthesis of 17b Estrasdiol and the enzyme is 
overexpressed in many breast cancers[87]. Two types of AIs are used clinically, Type I and Type 
II, both of which block the production of E2. Type I AIs are structurally similar to 
androsetendione, which is a natural substrate for aromatase. The enzyme acts on the Type I AI 
and produces an irreversible covalent bond which prevents the synthesis of E2. Type II AIs on 
the other hand do not use an irreversible mechanism of action. Rather, Type II AIs are 
competitive inhibitors which do not resemble steroid molecules. They can be displaced with an 
increase in androgen synthesis. The complete mechanism by which Type II inhibitors work is not 
know but it has been show that they functionally inactivate a heme group within the enzyme[13]. 
Both Type I and Type II AIs are used after 5 years of tamoxifen treatment and are useful in the 
treatment of tamoxifen resistant breast cancers[88]. However, because of their systemic effects 
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on estrogen production they have an unfavorable side effect profile and are considered later in 
therapeutic progression.  
 The ability to target a singular receptor through multiple mechanisms of action evidences 
the importance of ERa as a key factor in the growth and progression of breast cancer. The 
mechanisms of targeting estrogen receptor also highlight the importance of displacing the 
endogenous ligand. Both major classes of clinically relevant endocrine therapy block the action 
of E2 with relation to estrogen receptor as much as they block the action of ER itself. 
1.8 Current work 
In the following chapters we describe current work to answer key questions in the E2-
ERα field.  Our efforts have led to the development of assays that allow us to study the direct 
biological effects of ERα in vitro using concentrations of E2 similar to those seen in post-
menopausal women. We find that 5 pM E2 promotes the growth of breast and ovarian cancer 
cells. These assays have also allowed us to study the effect of low E2 on the various pathways of 
ERα action including the extra nuclear and genomic pathways. We have been able to study the 
effect on low concentrations of E2 on gene transcription in order to study differences in gene 
regulation of putative ERα target genes. While these studies have shed light on a number of 
issues related to ERα and estrogen concentrations, they have also opened up new avenues of 
research on estrogen receptor dynamics at sub-saturating ERα concentrations that were 
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Physiologic Concentrations of 17β-Estradiol Induce Cell 
Proliferation via Estrogen Receptor α 
2.1 Abstract 
Estrogen Receptor (ER) plays an important role in the growth and progression of breast cancer 
and, as evidenced by the success of tamoxifen, an important adjuvant therpay. The clear majority 
of ER positive breast cancers occur in postmenopausal women when 17β-estradiol (E2) levels are 
at their nadir. Epidemiological studies have established that the level of E2 necessary to increase 
the risk of a woman developing breast cancer is much lower than the reported Kd of estrogen 
receptor and lies within the picomolar (pM) range. We show that in-vitro the levels of estrogen 
in concordance with those seen in postmenopausal women elicit robust proliferation of several 
breast cancer cell lines in both 2D and 3D cell culture models. Using pharmacological inhibitors 
of ER and siRNA knockdown, we demonstrate that these effects are mediated through ERα. We 
also demonstrate that these effects are primarily mediated through estrogen receptor’s nuclear 
effects and are not via ER’s extra-nuclear activation of ERK. These results indicate that only a 
very small fraction of the total receptor population needs to be ligand bound in order to induce 







Breast cancer is the second leading cancer in the United States with almost 40,000 new 
cases annually[1]. Two key players in the growth and progression of breast cancer are estrogens 
and Estrogen Receptor (ER)[2, 3].   
Estrogens normally produced by the ovary and adrenal gland, act via estrogen receptor 
and play a critical role in the development and progression of breast cancer[3, 4].  The 
endogenous estrogen, 17β-estradiol (E2), binds ERα and creates an E2-ERα complex. This 
complex exerts effects directly on the genome as well as through extra-nuclear effects which 
activate intracellular signaling cascades both of which ultimately promote the proliferation of 
breast cancer cells[5]. 
The classic pathway of E2-ERα action is via the nuclear pathway. When E2 binds to ERα, 
localized in the nucleus, this causes dissociation of heat shock proteins from the unlignaded 
receptor and recruitment of ERα to form DNA-bound transcriptional complexes. ERα can bind 
directly to DNA at palindromic sites termed Estrogen Response Elements (ERE), or it can bind 
to basal transcription factors such as the AP-1, SP-1 or FOXA1 family of transcription factors in 
a mechanism known as tethering[6-10]. Ultimately this leads to transcription of ER target genes 
important for several biological functions including proliferation. 
The second method by which the E2-ERα complex exerts its influence on the cell is via 
the extra-nuclear or rapid pathway. Here E2 bound ERα interacts with a multitude of signaling 
cascades outside the nucleus to quickly initiate signaling events[11, 12]. The classic extra-
nuclear target of E2-ERα is the activation of the ERK 1/2 pathway which promotes 
phosphorylation of transcription factors and downstream MAPK targets[13]. 
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Despite our understanding of the various pathways E2 regulates via ER we still don’t 
understand how activation of those pathways may vary over the life time of a woman. The vast 
majority of women who develop ER+ breast cancer are postmenopausal[14]. This is when 
circulating estrogen concentrations are at their lowest. Improved methods for detecting and 
quantitating circulating estradiol levels in blood have led to several papers which highlight the 
surprising finding that picomolar levels of circulating estrogens increase the risk of breast cancer 
[15-19]. Most prominently a JAMA article demonstrated that compared to undetectable levels 
(<1 pM), a serum estradiol level of 10 pM increased the risk of developing breast cancer by 6.9 
fold[20].  
While the epidemiologic data is robust and compelling, it is not clear whether these levels 
of E2 can induce proliferation of breast cancer cells, or merely increase the risk of developing 
breast cancer. In order to assess this, we developed a cell culture based system in which the cells 
are completely dependent upon estrogens for their growth. Using this assay we could then test 
whether concentrations of E2 well below the Kd for binding to ER (~0.5 nM) could stimulate cell 
proliferation[21, 22].  
2.3 Materials and Methods 
Cell culture 
Cells were maintained in MEM supplemented with 10 mM HEPES and either 5% (MCF-7 and 
BG-1) or 10% (T47D) FBS. 4 days prior to plating cells were cultured in MEM supplemented 
with 5% (MCF-7 and BG-1) or 10% charcoal-dextran-treated (CD)-FBS.  
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Cell proliferation assay 
Cells were cultured in charcoal dextran stripped media as described above. Cells were 
trypsinized and re-suspended in 10% CD Calf Serum.  Cells were plated in a 96-well plate at a 
density of 1,000 cells/well (MCF-7), 2,000 cells/well (T47D and T47D D538G) or 200 cells/well 
(BG-1). After 12 hours the plating media was removed and replaced with media containing the 
desired treatment in 10% CD-CS . After 3-4 days the cells were incubated with Cell Titer 96 
Aqueous One Solution (Promega) (MTS assay) and analyzed using a spectrophotometric plate 
reader at 490 nM and 650 nM. A standard curve was always performed to correlate cell number 
to the absorbance reading. Proliferation was confirmed by visual observation of each well. 
Soft agar colony formation assay 
To assay anchorage-independent cell growth in soft agar, 1 and 0.7% Select Agar (Invitrogen) 
was prepared in water and warmed at 40° C before use. 1.5 ml of 0.5% bottom agar, diluted in 
2× MEM, was added to each well of a 6-well cell culture plate and allowed to solidify at room 
temperature. Top agar was prepared by dilution in warm medium. MCF-7 cells were 
resuspended in 1.5 ml of 0.35% top agar at 6,000 cells/well and plated in 3 wells for each 
condition. The plates were kept at room temperature for 30 min until the top agar solidified, then 
0.5 ml of medium containing the respective treatments was added on top of the agar. Culture 
medium containing the treatments were changed every 2-days. Colonies were visible after 2 
weeks in the hormone-treated wells and counted at day 28 using a dissecting microscope. 
Photographs of colonies ERa in each cell line were taken using a Zeiss AxioImager2 imaging 





25,000 MCF-7 cells were plated in antibiotic free 5% CD-FBS in a 24-well plate. The cells were 
allowed to adhere overnight.  The cells were treated with 5 nM Faslodex/ICI 182,780 (Sigma) 
for 12 hours before initiation of the transfection protocol. Cells were treated with 50 nM of ERα 
siRNA, 50 ng of scrambled siRNA or liposome alone. Cells were treated with transfection 
complex for 16 hours after which the complex was removed and replaced with antibiotic-
free10% CD-CS. Cells were then plated in 96-well plates for treatment and analysis of cell 
proliferation/MTS assay alongside a standard curve. 
Western blot analysis  
Cells were cultured in 5% CD-FBS (MCF7 and BG-1) or 10% CD-FBS (T47D) for 4 days prior 
to being plated at 300,000 cells/well in 6-well plates in medium containing 10% CD-CS. Whole 
cell extracts were prepared after 24 h of treatment using 1× radioimmune precipitation assay 
buffer (Millipore) containing complete mini protease inhibitor mixture (Roche). 30 µg of protein 
per lane was analyzed on 10% SDS-PAGE gels and transferred to nitrocellulose membranes (GE 
Healthcare). Phospho0p44/42 MAPK (4370) p44/42 MAPK (4695), ERa was detected using 
Santa Cruz (8002) monoclonal antibody T1699 (Sigma), and β-actin was detected using antibody 
A1978 (Sigma). 
Statistical analysis 




Picomolar levels of 17β-estradiol induce proliferation of breast and ovarian cancer cells 
In a mouse xenograft model for breast cancer, MCF-7 tumors exhibit complete 
dependence on the presence of estrogen for growth[23-25]. In contrast, under standard cell 
culture conditions, MCF-7 cells grown in the absence of added E2 actively divide and simply 
grow more rapidly after treatment with E2[25] . Studies performed in dozens of laboratories over 
the last 30 years reveal a wide range of dose-response curves that have been reported for E2 
stimulation of the growth of MCF-7 cells[26, 27]. I, and others in our laboratory, developed a 
number of techniques to more nearly simulate breast cancer proliferation conditions in the intact 
animal and eliminate traces of estrogens from the culture system. In my experiments, growth of 
MCF-7 cells is completely dependent on addition of E2 to the culture medium. I reproducibly 
find that concentrations of E2 in the low picomolar range stimulated growth of the MCF-7 cells. 
Half-maximal stimulation of growth was achieved at ~0.5 pM E2 and maximal stimulation of 
MCF-7 growth was achieved at 5 pM E2 (Fig. 2.1 A). 
To test whether the surprising finding that picomolar E2 stimulates growth of MCF-7 
cells reflects a unique property of these cells, or is a more general phenomenon, I performed 
dose-response studies of the effects E2 on the growth of T47D human breast cancer cells, the BG-
1 variant of breast cancer cells and a mutant T47D D538G cells derived from wildtype T47D 
cells. Maximal cell proliferation was achieved at 10 pM E2 for T47D cells, nearly 10 pM E2 for 
T47D D538G cells and 20 pM E2 for BG1 cells growth was achieved while maximal 
proliferation (Figure 2.1 B, C, D). While the MCF-7, T47D and BG1 cells did not demonstrate 
estrogen independent growth the T47D D538G cells did proliferate in the absence of E2. 
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While the importance of estrogens and estrogen receptor are well described in breast 
cancer due to the efficacy of endocrine therapies, ovarian cancers represent another often-
overlooked area where the E2-ERa signaling pathway are important. 30-70% of ovarian tumors 
are ER+, rely on the expression of estrogen receptor but are insensitive to endocrine therapies[28-
30]. PEO4 cells are one model of ovarian cancer that are known to estrogen responsive in cell 
culture [31]. PE04 cells plated in our cell culture system demonstrate near maximal estrogen 
inducible growth at 50 pM (Fig. 2.1 E). The resulting data demonstrates that both breast and 
ovarian cancer cells are induced to near maximal proliferation by picomolar concentrations of E2. 
Estrogen receptor levels correlate with the concentration of E2 required to stimulate 
proliferation  
In each cell line pM estrogen elicited robust proliferation. To test whether differences in 
E2 concentration required to induce maximal stimulation of cell proliferation was related to the 
level of ERa, we determined the level of ERa in each cell line. Figure 2.2 shows that receptor 
levels in the T47D and BG1 cells are roughly half and one third, respectively, of the ERa level 
in MCF7 cells. The T47D D538G derived from the wildtype T47D cells have been shown to 
have a similar level of ER[32]. Thus, ERa levels show an inverse correlation with the 
concentration of E2 necessary to induce maximal proliferation. The results also correlate with the 
fact that approximately twice the amount of estrogen was necessary for maximal proliferation of 
the T47D cells compared to the MCF-7 cells.  
Picomolar estrogen stimulate anchorage independent growth 
While 2D cell culture assays are robust tools for studying the division of cells they cannot 
completely recapitulate all the properties of a 3-dimensional tumor.  An in vitro surrogate of 
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tumor xenografts are soft agar or colony formation assays. These 3-dimensional cultures 
recapitulate 2 essential features of cancer cells. The first is anchorage independent growth of 
tumor cells while the second is clonal outgrowth of a single tumor cell[33, 34].  
In order to provide a more rigorous and physiologic test of the ability of pM E2 to induce 
cell proliferation, we performed soft agar assays (Figure 2.3). Using no estrogen (-E2), 10 nM E2 
and 10 pM E2 we observed that pM concentrations of E2 stimulate the formation of colonies >0.5 
mm in diameter. Comparing the number of colonies >0.5 mm between treatment groups, there 
was a statistically significant (P<0.05) difference between the -E2 and either the pM E2 or nM E2 
groups (Figure 2.3 C). However, there was not a significant difference in the number of colonies 
formed between the groups treated with pM and nM estrogen. This demonstrates that low 
concentrations of estrogen in the physiological range of postmenopausal women promotes 
anchorage independent growth of breast cancer cells. 
Picomolar estradiol functions via ERα 
To explore whether the effects of pM E2 were mediated through ERa, or via a new novel 
mechanism of action, we inhibited estrogen dependent growth utilizing the competitor 
antiestrogen ICI 182,780/Faslodex/fulvestrant and our novel non-competitive small molecule 
ERa inhibitor, TPSF[35, 36]. TPSF is a specific small molecule inhibitor of ER alpha identified 
via in vitro screening that works outside the ligand binding pocket of ERa. This is in contrast to 
ICI 182780/Faslodex/fulvestrant which competes with estrogens for the ligand binding pocket of 
ERa [37, 38]. These two inhibitors work via different mechanisms of action but each inhibited 
estrogen dependent cell proliferation (Figure 2.4 A) indicating the effects of picomolar estradiol 
are mediated through ERa.  
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To more directly assess the role of ERa in estrogen-dependent cell proliferation induced 
by pM E2, we performed an siRNA knockdown of ERa in MCF-7 cells. Because our data 
suggest a tiny fraction of ERa bound with E2 is sufficient to stimulate cell proliferation and 
significant protein remains even after RNAi knockdown, we used pre-treatment with ICI 
182,780/Fulvestrant to degrade the ERa already present and subsequently inhibited the synthesis 
of new ERa with siRNA. ICI alone reduced, but did not eliminate estrogen-induced cell 
proliferation over the course of the experiment. However, the combination of ICI pre-treatment 
with siRNA knockdown completely blocked cell proliferation induced by pM E2 (Figrue 2.4B). 
The non-coding (NC) control siRNA had no effect. 
EGF does not potentiate pM E2 induced proliferation  
While estrogens binding to estrogen receptor activate gene transcription, post 
transcriptional modification of ER facilitates its downstream effects. Maximum activation of ER 
requires by phosphorylation of the receptor via ERK 1/2  phosphorylation at Ser-118 and Ser-
167[39]. To test whether the EGF pathway could potentiate the effects of low concentrations of 
E2, MCF7 cells were treated with levels of E2 below which maximal cell proliferation was 
observed given our dose response curves  
The results (Figure 2.5) show that addition of 100 ng/ml EGF to the medium did not 
potentiate the effect of low concentrations of E2.  With and without EGF the cells achieved the 
same level of proliferation. Thus activation of the ERK pathway by addition of EGF does not 
further stimulate proliferation induced by pM E2. These data indicate that, acting via ERa, pM 
E2 is sufficient to induce maximal proliferation of ERa positive cancer cells 
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Activation of the ERK pathway moderately contributes to E2 induced proliferation 
ER has many effects outside the nucleus including activation of the ERK pathway[12] . 
E2 binding to ER can cause ERK to be phosphorylated and activated, which in turn can 
reciprocally maximally activate the receptor. To assess the contribution of ERK activation to 
proliferation induced by pM E2, we used the ERK1/ 2 inhibitor, U0126[40]. Pretreating cells 
with U0126 before the addition of low and high E2 demonstrated that the major pathway of 
proliferation is not via the ERK 1/2. Interestingly, the ERK pathway contributed to 
approximately 30% of the growth induced by pM estrogen (Figure 2.6 A and B).  Western blot 
demonstrated U0126’s ability to inhibit phosphorylation of the p44-42 MAPK. The data 
demonstrate that the ERK pathway activity contributes to low E2 induced proliferation but is not 
the major pathway of E2-ER proliferation.  
GPR 30 inhibits pM E2 induced proliferation 
GPR 30 also known as G-Protein Estrogen Receptor (GPER) is a G-Protein Coupled 
Receptor (GPCR) that that binds estrogen and is localized to the membrane of the endoplasmic 
reticulum[41-45]. However, its role in estrogen dependent growth has been controversial with 
some studies indicating that it is an important pathway for estrogen dependent growth while 
other studies indicate it has minimal importance for estrogen induced proliferation. To assess the 
role of GPR30 in pM E2 induced proliferation, we used a known synthetic agonist of GPR30, 
G1. In the absence of E2, G1 did not stimulate proliferation of MCF-7 cells. Surprisingly, while 
G1 is an agonist of GPR30 our demonstrated that it robustly inhibited proliferation induced by 




Recent advances in the measurement of estrogen levels from patient samples have 
revealed that the concentrations of estrogens necessary to increase the risk of breast cancer in 
postmenopausal women are in the picomolar range[16-18, 20-22]. However, it was unclear 
whether these levels of E2 could stimulate the proliferation of breast cancer cells in vitro.  
Here we describe a model for estrogen dependent growth of breast and ovarian cancer 
cancer cells in which cell proliferation is entirely dependent upon the addition of E2 to the 
growth medium. This cell culture model recapitulates the observation that in mouse xenograft 
models MCF-7 breast cancer cells fail to proliferate without the addition of estrogen[23, 24]. 
These assays reveal that picomolar concentrations of estrogen maximally stimulate the 
proliferation of breast cancer cells in 2D cell culture. This data correlates with human subjects 
data regarding the level of free E2 in serum of postmenopausal women. Similar results were 
obtained in 3D clonogenic assays of estrogen dependent growth (soft-agar assays).  
Using the specific ERα antagonists ICI 182 780 and TPSF along with siRNA 
knockdown, we demonstrate that ERa mediates cell proliferation induced by picomolar E2. 
MCF-7 cells treated with the antagonists ICI and TPSF failed to grow. siRNA knockdown was 
achieved without the control siRNA compromising the ability of the cells to proliferate. 
Consistent with a role for ERa, we found that cells which contained higher levels of ERa 
required lower concentrations of E2 to maximally stimulate proliferation.  
We also assessed the contribution of pathways outside of the classical mechanism of ER 
activation, specifically the extra-nuclear ERK pathway. Our results indicate that activation of the 
ERK1/2 pathway is a contributor to the proliferation of breast cancer cells but is not the major 
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pathway by which E2 functions. This would correlate with previous data demonstrating that an 
estrogen dendrimer conjugate (EDC), only capable of activating the extra-nuclear effects of ERα, 
was minimally effective in stimulating cell proliferation[46].  
Another alternate pathway of E2 action that has been extremely controversial has been 
GPR 30. GPR 30 was originally reported as causing breast cancer cells to grow. However, recent 
literature has revealed that the binding affinity of GPR30 for E2 is extremely high and that it 
appears to inhibit proliferation in ERα positive breast cancer cells when activated[43].  Here we 
show that activation of GPR30 through a specific ligand, G1, does not stimulate proliferation of 
ER positive breast cancer cells, actually inhibits their growth similar to recent articles and, 
therefore, could not be the pathway responsible for low E2 induced proliferation. 
Our data indicates that E2 and ER function far below the Kd of the receptor for E2.  The 
data results suggest that stimulating cell proliferation requires a threshold number of ERα 
molecules that must contain bound E2. How this threshold is reached differs for each cell type 
and is a function of the intracellular level of ERα and the concentration of E2. Although ERα 
binds to at least 10,000 sites in the human genome[47], our data suggests that far less than 
10,000 molecules of E2-ERα per cell is sufficient to robustly induce cell proliferation.  
These results highlight the biological importance of low circulating levels of free E2 in 








Figure 2.1. Picomolar concentrations of 17β-estradiol elicit near maximal proliferation of 
breast and ovarian cancer cells. Dose response curves were performed on (A) MCF-7 (B) T47-
D and (C)T47D D538G and (D) BG-1 cells. 1,000 MCF7 cells were plated per well and treated 
with the indicated concentrations of E2 for:  3 days for MCF7 cells, 4 days for T47D, and 7 days 
for BG1 cells. Then proliferation was analyzed using MTS reagent. Plating cell number was 
1,000 for MCF7, 2,000 for T47D, 2000 for T47D D538G, 200 for BG1 and 500 for PE04 cells. 









Figure 2.2. Western blot of ERa protein levels. Cells were plated and maintained for 4 days in 
CD-FBS and plated into 10% CD-CS. 12 hours after plating cells were treated with 10 nM E2 for 
12 hours and whole cell extract was collected. 20 µg of lysate was resolved on a 10% PAGE and 


















Figure 2.3. 3-dimensional proliferation assay reveals tumorigenic potential of low E2. 
Colony formation assays in soft agar assess anchorage-independent growth and clonal outgrowth 
properties of tumors. MCF-7 cells were treated with either 10 pM or 10 nM E2 for a period of 21 
days. The results of the experiment showed no statistically significant difference in colony 
forming ability between the Low (10 pM E2) and High (10 nM E2) groups. However, the low and 
high groups showed statistically significant increases in colony formation over the (-)E2 group 












Figure 2.4. Inhibition of ERα abrogates proliferation induced by pM E2. (A) Cells were 
maintained in the ERα specific pharmacologic antagonists ICI 182,780 and TPSF for 3 days, 
with or without E2, and cell number assayed using MTS. (B) 5nM ICI 182,780 was pre-
incubated with cells for 12 hours to degrade endogenous ER before siRNA knockdown of ERα 
was initiated. Cells were transfected for 16 hours before being removed and re-plated in 96 well 
plates for growth assays. Cells were treated with E2 after 12 hours of recovery and analyzed 
using MTS reagent after 3days. (C) Western blot of ER alpha and Actin after siRNA knockdown 










Figure 2.5. EGF does not potentiate proliferation induced by pM E2. To study the effect of 
ERK kinase activation, MCF7 cells were treated with 100ng/mL EGF. Cells were incubated with 
EGF or without EGF and varying concentrations of E2. Cells were assayed using MTS reagent 3 
















Figure 2.6. The MEK 1/2 U0126 inhibitor partially blocks E2 Induced Proliferation. MCF-7 
cells were pretreated with 10µM U0126 for 2 hours before treatment with E2 or one of 2 ER 
specific antagonist A.) TPSF B.) ICI 182,780/ Fulvestrant. Cells were assayed after 3 days with 
MTS reagent. Results are displayed as mean ±SEM of 3 independent replicates. (C) 20ug lysate 











Figure 2.7. GPR30 Agonist G1 Inhibits E2 Dependent Proliferation. MCF-7 cells were 
treated either with vehicle, G1 agonist alone or G1 in combination with 10 pM E2.  Cell number 
was determined using MTS reagent after 36 hours of treatment. Results are displayed as mean 
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Picomolar Concentrations of E2 Regulate Breast Cancer Gene 
Expression 
3.1 Abstract 
The circulating levels of 17β-estradiol (E2) normally found in postmenopausal women are in the 
low picomolar range as gathered from human sampling. However, it was unclear whether these 
extremely low E2 concentrations can stimulate gene transcription. Here we demonstrate that 
concentrations of E2 as low as 5 pM can stimulate gene transcription. Comparing the effect of 
picomolar and nanomolar concentrations of E2, we find several well-studied E2-estrogen receptor 
a (ERa)-regulated genes including pS2 and progesterone receptor (PGR) are induced by pM E2. 
We also find that pM E2 reduces expression of IL1R1, which is normally downregulated by E2-
ERa. However, expression of the E2-ERa-induced protoconcogene c-fos was not demonstrated 
at picomolar concentrations of E2. We also noted that 10 pM E2 was sufficient to induce the E2-
ERα cell cycle regulator, E2F1, at the protein level. Finally, we demonstrate that picomolar 
concentrations of E2 were as effective as nanomolar E2 in increasing recruitment of ERα to the 
GREB1 and pS2 promoters. This data demonstrates that picomolar concentrations of E2 able to 
ligand only a very small fraction of intracellular ERα pool are sufficient to regulate expression of 
several estrogen-responsive genes. Since pM E2 induces robust proliferation of ERα positive 
cancer cells, differential regulation of E2F1 and cFos suggests that the ability to elicit gene 
regulation at post-menopausal physiologic concentrations. Therefore, pM E2 represents a novel 
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way to identify genes likely to play a role in estrogen-stimulated proliferation of cancer cells and 
exclude genes unlikely to play a role.  
3.2 Introduction 
Estrogens acting via the steroid nuclear receptor, estrogen receptor a (ERa), are 
extremely important in the growth and development of breast cancer[1]. The importance of ER is 
evidenced by the fact that mainstay adjuvant therapies target estrogen-ERa via a variety of 
mechanisms.  The first method is to block E2 binding to ER. This is accomplished by drugs such 
as tamoxifen, raloxifene, and ICI 182780/Faslodex/fulvestrant that compete with estrogens for 
binding to ERa[2, 3]. The second is to starve cells of E2 by inhibiting aromatase, the enzyme 
responsible for the conversion of testosterone to 17b-estradiol [4]. Through either mechanism, 
the end goal is blocking formation of the E2-ERα complex which has proven critical for treating 
breast cancer. It also highlights the importance of the hormone-steroid receptor complex in 
driving proliferation of breast cancer cells.  
Classically the E2-ERα acts via direct regulation of gene transcription.  E2 and other 
estrogens produced by the ovary and the adrenal gland bind to estrogen receptors localized in the 
nucleus. Binding of estrogens to the Ligand Binding Domain (LBD) of estrogen receptors 
induces a conformational change in the receptor. The conformational change allows for homo-
dimerization of the receptor. The receptor dimer can then be recruited to DNA either at 
palindromic Estrogen Response Elements (ERE) or it can be tethered to DNA through binding to 
other transcription factors that bind DNA[1, 5-7]. The Activation Function 1 and 2 (AF1 and 
AF2) domains of the receptor facilitate recruitment of co-activator proteins that aide in assembly 
of the transcription complex[8, 9].  
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Both pre and postmenopausal women develop ERα positive breast cancer. However, the 
majority of women who develop ERα+ breast cancer are post-menopausal[10]. At the point a 
woman reaches menopause the levels of estrogenic steroid hormone produced are at their 
nadir[11-13].  A number of recent studies utilizing newer, more accurate techniques have 
demonstrated that concentrations of circulating E2 necessary to increase the risk of breast cancer 
lie in the low picomolar range[14-17].   
Chapter 2 demonstrated that picomolar concentrations of E2 could illicit near maximal 
proliferation of breast cancer cells. The data showed that these miniscule levels of estrogen did 
not exert their major function via the extranuclear pathway. This implies that the major axis by 
which picomolar levels of estrogen exert their effect is via classical ERα action in the nucleus. 
However, it has been suggested that these E2 concentrations are too low to induce E2-ERα 
dependent transcription. The data also imply that a threshold of ER saturation must be achieved 
in order to elicit proliferation of ERα positive breast cancer cells. To fully assess and understand 
the effect of low E2 concentrations on gene transcription, we undertook a series of studies that 
looked not only at concentration dependent gene transcription but also sought to identify 
differentially regulated genes within the E2 -ERα target universe important for breast cancer cell 
proliferation. 
3.3 Materials and Methods 
Cell culture 
Cells were maintained in MEM supplemented with 10 mM HEPES and either 5% (MCF-7 and 
BG-1) or 10% (T47D) FBS. 4 days prior to plating cells were cultured in MEM supplemented 
with 5% (MCF-7 and BG-1) or 10% charcoal-dextran treated CD-FBS. 
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RNA isolation 
Cells were grown for 4 days in 5% CD-FBS (MCF-7 and BG-1) or 10% CD-FBS (T47D). Cells 
were trypsinized and transferred to a 6-well plate at 60% confluency in 10% CD-CS. Cells were 
allowed to adhere for 12 hours and then medium containing the indicated treatment conditions 
was added to the cells.  Cells were lysed and RNA was purified using the mini-RNAeasy kit 
(Qiagen). RNA was quantified using spectrophotometer and a minimum A260/A280 ratio of 1.8 
was used to as a cutoff for RNA.  
cDNA Synthesis and qRT-PCR 
1 µg of isolated RNA was reverse transcribed to cDNA using a cDNA synthesis kit (NEB).  50 
ng of reverse transcribed cDNA was loaded in each reaction in a 96-well plate, along with Sybr 
green (Roche) and 150 nM of gene-specific primers (Table 1).  Reactions were run as a 2 step 
PCR reaction on an Applied Biosystems Step One Plus Real Time PCR system for 40 cycles at 
90°C for 15min;  the resulting C(t) values were compared using the DDC(t) method[18]. 
Western blot 
Cells were cultured in 5% CD-FBS (MCF7 and BG-1) or 10% CD-FBS (T47D) for 4 days prior 
to being plated at 300,000 cells/well in 6-well plates in medium containing 10%CD-CS. Whole 
cell extracts were prepared after 24 h of treatment using 1× radioimmune precipitation assay buffer 
(Millipore) containing complete mini protease inhibitor mixture (Roche). 30 µg of protein per lane 
was analyzed on 10% SDS-PAGE gels and transferred to nitrocellulose membranes (GE 
Healthcare). E2F1 protein was detected using E2F1 antibody 3742 (Cell Signaling), internal 
control α-tubulin was detected using monoclonal antibody T1699 (Sigma), and β-actin was 
detected using antibody A1978 (Sigma). 
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ChIP 
MCF-7 cells were maintained in 5% CD-FBS for 3 days and treated with 10 nM E2, 10 pM E2, or 
Vehicle for 45 min. Cells were cross-linked with 1% formaldehyde for 15 min. Cell extracts were 
digested for 10 min with 50 units of micrococcal nuclease (NEB) at 37 °C and further sonicated 
to yield sheared DNA fragments with an average length of 200–1000 base pairs. The sonicated 
samples were pelleted by centrifugation, and the supernatant was diluted 5-fold with ChIP dilution 
buffer (0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM Tris-HCl, pH 8.1, 167 mM 
NaCl, and protease inhibitor mixture). 50 µl of diluted supernatant was reserved as input (10%) 
for each treatment. The samples were precleared with 50 µl of protein A-Sepharose™ 4 Fast Flow 
(GE Healthcare) in ChIP dilution buffer (1:1) preblocked with 200 µg/ml sheared herring sperm 
DNA and 500 µg/ml BSA. The samples were then divided, and the remaining proteins were 
incubated with either 2 µg of anti-ERa (C19), 2 µg of anti-RNA polymerase II (clone CTD4H8, 
Millipore), or control mouse IgG overnight at 4 °C. The antibody-protein-DNA complex was 
precipitated by incubating with 50 µl of Protein A-SepharoseTM beads for 2 h at 4 °C. The protein-
DNA complex was eluted from the beads with elution buffer (1% SDS, 0.1 M NaHCO3). Cross-
links were reversed, and DNA was eluted from the protein-DNA complexes by adding 200 mM 
NaCl and incubating overnight at 65° C. Protein was digested by incubation at 45 °C for 2 h with 
Proteinase K. DNA was recovered and purified. Quantitative PCR was performed to determine the 
change in ERa and RNA polymerase II occupancy at various sites of ERa binding. The double 
negative controls were nonspecific antibody (normal mouse IgG) and primers coding for intergenic 
regions that do not interact with ERa. Thermal cycling conditions were 95 °C for 10 min followed 
by 50 cycles of 25 s at 95 °C, 30 s at 60 °C, and 30 s at 72 °C. 
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Statistical analysis 
All statistical analysis was performed using two-way ANOVA with Bonferroni correction. 
3.4 Results 
Dose-response study of E2 induced transcription  
 Since it is not fully understood whether E2 concentrations far below the Kd of estrogen 
receptor can stimulate the transcription of genes it was important to ascertain the concentrations 
of E2 that could induce transcription. As a test gene we chose the classic readout of E2-ERa 
mediated gene expression, pS2. pS2 is regulated directly by E2-ERa through direct DNA 
binding at Estrogen Response Elements (EREs). The data (Figure 3.1) demonstrate that at E2 
concentrations in the physiologic postmenopausal range induce transcription of the well-studied 
E2-ERa regulated gene, pS2.  (15). E2 stimulated detectable levels of pS2 mRNA at 5 pM and 10 
pM E2. However, E2 failed to induce pS2 mRNA at 1 pM E2. Interestingly, concentrations of E2 
in the femtomolar range that we show stimulate half maximal proliferation of MCF-7 cells 
(Chapter 2) did not have any effect on pS2 gene transcription. 
Maximal induction of pS2 mRNA occurred at 100 pM E2 and not 1000 pM E2. While 
this was surprising it does correlate with previous data regarding peak levels of E2-ERa induced 
gene transcription in artificial systems[19, 20]. In those systems, a stably transfected luciferase 
reporter with 3 Estrogen Response Elements reached maximal luciferase activity at 50 pM E2. 
This would suggest that hormone concentration and transcription are not linearly related at all 
levels of E2. The data clearly demonstrate that physiologic concentrations of 17β-estradiol can 
stimulate gene transcription, but gene expression does not reach the levels seen at higher E2 
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concentrations. This also indicates that E2 can exert its classical effects far below the measured 
Kd for binding of E2 to ERa [21, 22]. 
Time course of E2-ERa induction of MCF-7 gene expression  
Given that only a small fraction of the total estrogen receptor population is ligand bound 
at picomolar concentrations of E2 and that this fractional population is capable of stimulating cell 
proliferation and gene expression, it would be reasonable to extrapolate that only a fraction of the 
ERα transcriptome is being transcribed at low concentrations of E2[23] . The transcriptome 
would include putative ERα genes important in proliferation. Therefore, using qPCR we 
investigated differential regulation of genes at low E2 (10 pM E2) and high E2 (10 nM E2).  
The data (Figure 3.2 A-D) show a sample of genes tested.  Figure 3.1B reveals that pM 
E2 robustly stimulated the transcription of the pS2/TFF1 gene to a fold induction not previously 
reported in the literature. However, since the biological function of pS2 is not well defined, we 
wished to assess E2-ERa-regulated genes with known biological functions. Therefore, we looked 
at progesterone receptor (PGR), cMyc, Cyclin E2, cFos, Cyclin D1, and IL1R1 all of which are 
reported ERα targets (Figure 3.2 A-F)[24-28]. PGR (Figure 3.2A) mRNA was induced at both 
low and high E2; with the fold induction al 10 pM E2 approximately one half the maximum seen 
at 10 nM E2. cMyc another putative ERa target demonstrated close to 100-fold induction with 
nM concentrations of E2 but was not nearly as well induced by picomolar concentrations (Fig 
2B). However, c-fos, a gene proposed as a critical mediator of E2-ERa induced proliferation was 
not measurably induced by 10 pM E2 but remained responsive to E2-ERa at 10 nM E2 (Fig 
1C)[29].  According to this data, since 10 pM E2 induced robust proliferation of MCF-7 cells 
induction of c-fos does not play a central role in E2-ERa stimulated cell proliferation 
 61 
E2-ERa complex can both increase the expression of certain genes and decrease the 
expression of other genes. ER downregulates genes through tethering mechanisms and not via 
direct interaction with DNA. To understand whether picomolar E2 could downregulate a known 
ERα target gene we chose IL1R1, which is known to be downregulated at nanomolar 
concentrations of E2[30]. E2-ERa diminished transcription IL1R1 mRNA at both high and low 
concentrations of estrogen (Fig. 3.1D).  
The qRT-PCR data demonstrates that the ligand-receptor complex at different 
concentrations of estrogen differentially regulates several E2-ERa target genes. This is true for 
target genes regulated by different mechanisms of action. Upregulated ERα target genes are 
known to act via direct DNA binding and tethering while downregulated genes are proposed to 
work solely via tethering mechanisms. 
 This data shows differential regulation of ERa target genes at different E2 
concentrations. The data also show that for a 1000-fold difference in E2 concentration there is 
only, in general, an ~50% difference in transcriptional activity demonstrating a dramatic 
distinction between ERa saturation and transactivation by ERa. 
E2F1 protein expression is stimulated by low E2 
To test whether increases in transcription of genes implicated in E2-ERa dependent 
proliferation of MCF-7 cells lead to increases in the level of protein expression, we carried out 
western blot analysis of a putative E2-ERa-regulated cell cycle progression gene, E2F1. The E2-
ERa-induced E2F1 gene has gained prominence as a critical cell cycle factor implicated in E2-
ERa induced cell proliferation[31]. 
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Western blot of E2F1 protein at low E2 (10 pM) and high E2 (10 nM) provided strikingly 
similar results. The E2F1 protein was expressed at 8 and 12 hours post E2 in both samples. 
Densitometry revealed no statistically significant difference between the levels of protein at 12 
hours of induction (Figure 3.3B). The levels of E2F1 protein demonstrate that picomolar E2 can 
stimulate the production of E2-ERa-regulated proteins. A 1000-fold difference in E2 
concentration, resulting in increased saturation of ERa with E2, had no effect on the level of a 
key E2-ERa induced protein.  
Increasing the E2 concentration 1,000-fold does not increase recruitment of E2-ERa to 
promoters 
qRT-PCR data provided information on the relative levels of target E2-ERa mRNAs. We 
wished to explore the influence of E2 concentration on ERα recruitment to promoters of E2-ERa-
regulated genes containing known EREs. Therefore, we conducted Chromatin 
Immunoprecipitation (ChIP) assays at 10 pM E2 and 10 nM E2.  
pS2 and GREB1 are two well studied estrogen regulated genes[32-36]. At 10 pM E2 and 
10 nM E2 ERa is recruited equally to the promoter of both genes (Figure 3.4). The increase in 
recruitment over the (-) E2 sample is statistically significant (p<0.001) for both high and low E2.  
Interestingly, for both genes RNA polymerase II recruitment, was ~50% lower at 10 pM E2 than 
10 nM E2-ERa. This correlates with the qRT-PCR data showing that induction of pS2 and 





In Chapter 2 we demonstrated that picomolar concentrations of E2 induce near-maximal 
proliferation of breast cancer cells and the major estrogen receptor axis through which 
proliferation is induced is via the classical genomic mechanism of ERa action. However, it was 
still poorly understood whether these minute concentrations of E2-ERa could lead to quantifiable 
induction of gene transcription. Here we provide direct evidence that picomolar concentrations 
induce transcription of known ERα target genes such as pS2 in a physiologically relevant of E2 
concentration. We also show that pM concentrations of E2 differentially regulate ERα target 
genes compared to high nanomolar concentrations. While genes such as pS2 and PGR are 
extremely responsive to a very low concentration of E2, we found that that c-fos, a putative 
oncogene, was not induced at low concentrations of E2 but was robustly induced at nanomolar 
concentrations of E2[29].  
 Picomolar concentrations of E2 were also able to induce the protein E2F1, a known cycle 
regulator which has been proposed to play an important role in E2-ERa-stimulated proliferation 
of cancer cells[31]. E2F1 showed a strikingly similar level and time course of induction at 
picomolar and nanomolar concentrations of E2 substantiated by densitometry.  
 ChIP studies on the GREB1 and pS2 promoters demonstrate that at low and high 
concentrations of E2, ERα is recruited equally to both promoters. However, the increase in 
recruitment of RNA polymerase II at low pM E2 was only half of that seen with high nM E2. 
RNA polymerase II recruitment was better correlated with the level of induced mRNA than ERa 
recruitment. These data suggest that because ER is readily recruited to the promoter of two genes 
it regulates directly via DNA interactions the rate limiting step in gene transcription may not be 
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the initial recruitment of E2-ERa to promoters. Instead, recruitment of co-regulator proteins and 
assembly of a transcription complex leading to RNA polymerase II may represent the rate-
limiting step.  
 Most of our studies take place over a thousand-fold range of E2 concentration, 10 pM and 
10 nM. Since the Kd for binding of E2 to ERα is ~0.5 nM, 10 nM E2 will saturate all the ERα with 
hormone, while only a very small percentage of the ERα will be saturated with E2 at 10 pM[21, 
22]. However, on some, but not all, genes this large difference in the percentage of ERα 
containing bound E2 only results in an approximately 2-fold change in the level of induced 
mRNA. This suggests that the percentage of ERα saturated with E2 has only a limited impact on 
biological outcomes at many genes in breast cancer cells.  
 While nearly all studies use saturating concentrations of E2 to analyze ERα recruitment to 
target genes, we show that physiologically relevant concentrations of E2 effectively recruit ERα 
to at least some estrogen regulated promoter regions. Our data complements and extends current 
epidemiologic data suggesting that picomolar concentrations of serum 17β-estradiol are 
correlated with a highly increased risk of breast cancer [14-17, 37]. However, this also has major 
implications for what remains unknown about breast cancer. The eminent cancer biologist, Dr. 
Robert Weinberg, in “The Biology of Cancer” states that, “breast cancer…has been the subject 
of extensive research, yet we still have only a vague understanding at the molecular level of how 
growth of these tumors is controlled”[38]. While Dr. Weinberg may overstate what is not known 
about breast cancer, he does point out that we have identified a large number of cell cycle 
regulators thought to be critical for E2 induced proliferation. Using our observation that some 
genes fail to exhibit regulation by low concentrations of E2, we can use expression-profiling to 
narrow down the ER target gene universe important for the proliferation of breast cancer cells 
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(Figure 3.5). This would allow one to exclude genes, such as c-fos that require nanomolar E2 
concentrations for regulation and include genes regulated both at picomolar and nanomolar 
concentrations of E2. 
 Furthermore, the data presented here is relevant to an important recent study indicating 
that that almost 15% of the genome is regulated by ERα[39]. While the conclusion that a major 
portion of the genome may be regulated by ER is probably correct the high 100 nM 
concentration of E2 used in that study suggests that there is a gradient of response to E2 as its 
concentration increases. Some genes, such as c-fos will only respond to E2 in vivo in cells 
containing high levels of ERα and during phases of the menstrual cycle or in pregnancy when 
levels of circulating levels E2 are high[12, 13]. At 10 pM E2 only a few hundred molecules of 
ERα will contain bound E2. At this concentration of E2, which is in the range seen in 
postmenopausal women, it is likely that only a fraction of the potential E2-ERα-regulated 
transcriptome responds to estrogen.  
Further understanding of the genes and mechanisms of regulation of E2 may allow us to 
explain differential actions of E2 over the course the hormone cycle. It is also possible that this 
may lead to answers regarding transcription dynamics that have recently raised[40]. Eventually 
characterizing the highly estrogen responsive fraction of the E2-ERα-regulated transcriptome 

























Figure 3.1. Dose Response and Time Course Study of E2-ERα induction of pS2 mRNA. 
MCF-7 cells were maintained in 5% CD-FBS for 4 days and re-plated in 10% CD-CS. Cells 
were treated with indicated concentrations of E2 for 4 hours, RNA was collected and reverse 
transcribed to cDNA and quantitated using the qPCR ΔΔ C(t) method. Data represent mean fold 
induction over (-) E2/Vehicle ±SEM. (A) pS2 dose response to varying doses of estrogen. (B) 







Figure 3.2. ERα Target Genes are Differentially Regulated by Low and High E2. MCF-7 
cells were maintained in 5% CD-FBS for 4 days and re-plated in 10% CD-CS. Cells were treated 
with high (10 nM ) E2 or low (10 pM) E2 for for 2, 4, 8, 12 and 24 hours. RNA was collected and 
reverse transcribed to cDNA and quantified using the qPCR ΔΔ C(t) method. Data represent 
mean fold induction over (-) E2/Vehicle ±SEM. (A) PgR (B) cMyc (C) CycE2 (D) cFos (E) 









Figure 3.3. A low concentration of E2 induces E2F1 protein. After 4 days in 5% CD-FBS, 
MCF-7 cells were plated in 10%CD-CS. Treatment medium containing 10 pM E2 or 10 nM E2 
was added to the cells. Lysate was collected at 2, 4, 8, 12, 24 hours using RIPA buffer. 40 ug of 












Figure 3.4. Low and high E2 concentrations result in equivalent ERa recruitment to EREs 
but decreased RNAPII recruitment. MCF-7 cells were maintained in 5% CD-FBS for 3 days 
prior to the experiment. Low E2 (10 pM E2) and high E2 (10 nM E2) were added to the cells for 
45 min. Protein complexes were crosslinked and immunoprecipitated using ERα antibody and 
RNAPII antibody.  Fold enrichment over IgG was plotted. Data represent the mean of 3 








Figure 3.5. Using Low E2 to catalog the ERα transcriptome. The venn diagram represents 
how we can use the low E2 and high E2 concept to narrow the ERα transcriptome. potential 
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A New Experimental Model in the Search for Genes E2-ERα Uses to 
Stimulate Cell Proliferation 
4.1 Abstract 
 Estrogens acting through Estrogen Receptors (ER) are critical mediators of breast cancer 
cell growth as evidenced by the effectiveness of tamoxifen and aromatase inhibitors as adjuvant 
therapies in breast cancer. While ER remains a viable therapeutic target, which genes ERα 
regulates to make breast cancer cells proliferate has remained an elusive question in the Estrogen 
Receptor field. The use of cell lines as tools to compare 17b-estradiol (E2) dependent and 
independent proliferation has been a mainstay in efforts to identify key genes. However, a major 
limitation in many systems has been either phenotypes are too subtle to fully characterize, or the 
cells come from diverse genetic backgrounds making identification of differentially regulated 
genes challenging. Here we describe a new tool which addresses many of the issues regarding 
the identification of downstream E2-ERα mediators. We have characterized two cell lines, wild 
type T47D cells and T47D-KBluc cells. The cell lines are nearly isogenic since the T47D-KBluc 
cells are derived from wild type T47D cells. The T47D-KBluc cells contain a stably transfected 
(ERE)3-luciferase reporter. However, unlike the parental cell line the KBluc cells do not 
proliferate in response to E2. We demonstrate that the ERα in the KBluc cells is functional on 
both the artificial reporter gene and on an endogenous gene. We also tested several ERα 
regulated genes proposed to have critical functions in ERα mediated growth. These genes did not 
exhibit differential regulation by E2 in the two cell lines, suggesting they are not responsible for 
the defect in E2 induced proliferation. Overall, we characterize a new experimental model that 
can assist in identifying E2-ERα regulated genes important in cell proliferation. 
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4.2 Introduction 
 The search for ERα regulated genes central to the growth of breast cancers has generated 
a variety of tools. These tools include cell lines derived from patient tumor samples. In the 
estrogen receptor field, the predominant cell lines studied are the T47D and MCF-7 cell lines. 
Each of these cell line is E2 dependent for proliferation as seen in the data in Chapter 2.  
However, to take advantage of expression arrays, RNA seq and bioinformatics a number of 
additional cell lines with unexpected or differential responses to E2 and ERα have been 
developed. 
Two of the most notable examples developed to tackle these problems have been the 
MDA-MB-231 ERα+ (231 ERα+) cells and the non-transformed MCF-10A ERIN cells (ERIN). 
MDA-MB-231 cells are triple a negative cell line (ER-/PR-/HER2-) which resulted in a unique 
phenotype. When these cells were stably transfected with ERa  proliferation is inhibited[1, 2]. 
The ERIN cells are a derived from immortal but non-tumorigenic MCF-10A cells. The ERIN 
cells have had ERα stably introduced, but the effects are modest[3].   
Both cell lines are successful models of the differential effects of ERα and allowed for 
the identification of ERα target genes important in proliferation. However, each has major 
limitations with their ability to identify genes important in E2 induced cell proliferation. While 
the MCF-10A ERIN cells grow in response to E2, proliferation is quite modest and the culture of 
these cells depends on several supplemented growth factors in addition to E2 [3]. Therefore, it is 
difficult to assess the contribution of E2 to growth as compared to the supplemented growth 
factors. In a recent paper characterizing the differences in gene regulation between MCF-7 and 
231 ERα+ cells, Prof. Benita Katzenellenbogen and coworkers acknowledged the limitations of 
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the system in recapitulating what was discovered in the 231 ERα+ cells back to a conventionally 
used cell line such as the MCF-7 cells[4]. This was likely due to large differences in genetic 
background of the two cell lines. These differences have limited the usefulness of most studies 
comparing different cell lines.  
Here we describe a potential new experimental model for use in the search for ERα 
regulated genes. We identified two nearly isogenic cell lines that exhibit a differential response 
to estrogens. The T47D WT cells were shown in chapter 2 to be dependent on estrogens for 
growth; with their proliferation stimulated by extremely low picomolar concentrations of E2. In 
contrast, proliferation of a sub-clone of the wild type cells, T47D-KBluc (KBluc) cells robustly 
proliferates without estrogen and is completely unresponsive to additional E2 under the same 
growth conditions. We characterize these cells and demonstrate the deficiency is not due to lack 
of biologically active ERα. Due to their nearly isogenic background and on/off phenotype these 
cell lines represent a useful new experimental model for investigations of genes and pathways 
important in E2-ERα stimulated cell proliferation. 
4.3 Materials and Methods 
Cell Culture 
T47D and T47D-KBluc cells were maintained in phenol red containing MEM supplemented with 
10 mM HEPES, pH 7.4 and 10% FBS. 4 days prior to plating cells were cultured in phenol red 




Cell Proliferation Assays 
Cells were cultured in medium containing charcoal dextran stripped serum as described above. 
Cells were trypsinized and resuspended in 10% CD Calf Serum.  Cells were plated in a 96-well 
plate at a density of 1,000 cells/well (MCF-7), 2,000 cells/well (T47D, and T47D-KBluc) or 200 
cells/well (BG-1). After 12 hours plating medium was removed and replaced with treatment 
conditions in 10% CD-CS . After 3-4 days the cells were incubated with Cell Titer 96 Aqueous 
One Solution (Promega) and analyzed using a spectrophotometric plate reader at 490 nM and 
650 nM. A standard curve was always performed to correlate cell number to absorbance. 
RNA Isolation 
T47D and T47D-KBluc cells were grown for 4 days in 10% CD-FBS. Cells were trypsinized and 
transferred to a 6-well plate at 60% confluence in 10% CD-CS. Cells were left for 12 hours to 
adhere and then treatment conditions were added to the cells.  Cells were lysed and RNA was 
purified using mini-RNAeasy kit (Qiagen). RNA was quantified using a spectrophotometer and a 
minimum A260/A280 ratio of 1.8 was used as a cutoff for RNA.  
cDNA Synthesis and qRT-PCR 
1 µg of isolated RNA was reverse transcribed to cDNA utilizing a cDNA synthesis kit (NEB).  
50 ng of reverse transcribed cDNA was loaded in each reaction in a 96-well plate, along with 
Sybr green (Roche) and 150 nM primers (Table 1).  Reactions were run as a 2 step PCR reaction 
on an Applied Biosystems Step One Plus Real Time PCR system for 40 cycles at 90° C for 




Cells were cultured in 10% CD-FBS (T47D and T47D-KBluc) for 4 days prior to being plated at 
300,000 cells/well in 6-well plates in medium containing 10%CD-CS. Whole cell extracts were 
prepared after 24 h of treatment using 1× radioimmune precipitation assay buffer (Millipore) 
containing complete mini protease inhibitor mixture (Roche). 30 µg of protein per lane was 
analyzed on 10% SDS-PAGE gels and transferred to nitrocellulose membranes (GE Healthcare). 
ERa was detected using SC8002 (Santa Cruz Biosceinces) and β-actin was detected using 
antibody A1978 (Sigma). 
4.4 Results 
Estrogen Does not Stimulate Proliferation of T47D-KBluc cells  
 T47D cells are a luminal breast cancer cell line described by Keydar et al in 1979[5]. 
This cell line has been a prominent cell culture model for ERα positive breast cancer. Therefore, 
these cells were a natural starting point for development of a stably transfected luciferase based 
screening system for evaluating the estrogenic potential of environmental compounds[6]. The 
resulting cell line, T47D-KBluc cells (KBluc), are a sensitive luciferase reporter system 
maintained without the use of a selection marker. 
 However, as the results (Figure 4.1) show, proliferation of the stably transfected KBluc 
cell line is not stimulated by E2.  This contrasts with the data shown in Chapter 2, where the wild 
type T47D cells proliferate in response to picomolar concentrations of E2. The KBluc cells grow 
normally in full serum (10% FBS), and like parental T47D cells do not proliferate in estrogen-
free 10% CD-CS used in cell proliferation assays. The KBluc cells neither proliferate nor 
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undergo apoptosis in response to E2. Instead, the cells remain quiescent when exposed to 
estrogens.  
 Therefore, these two cell lines provide a nearly genetically identical system in which we 
can study differential responses to estrogen treatment in order to identify genes that are important 
in E2-ERα induced stimulated cell proliferation. 
T47D KBluc Cells Contain Functional ERα 
Since KBluc cells were produced by another lab for a different purpose it is possible that 
there was inadvertent selection of a dysfunctional reporter. However, the evidence from the 
development of the KBluc cells[6] and their subsequent use in our laboratory for high throughput 
screening for ERα inhibitors suggests they contain functional ERα[7]. To confirm that ERa is 
present western blot analysis of the cells (Figure 4.2C) demonstrated that the KBluc cells contain 
estrogen receptor and the expression levels are similar to what is seen in their wildtype 
counterpart.  
The cells were stably transfected with a luciferase reporter containing three upstream 
Estrogen Response Elements (ERE) to drive the transcription of the firefly luciferase reporter 
(Figure 4.2A). Luciferase reporter data (Figure 4.2B) demonstrates that the (ERE)3-luciferase 
reporter is functional in these cells and they remain highly responsive to E2 on a transcriptional 
and translational level [6-9]. 
However, an artificial luciferase reporter does not completely recapitulate the cell-based 
mechanisms important in endogenous gene transcription. To assess whether ERα still functioned 
on an endogenous gene, qPCR was performed to see whether E2, acting through ERα, could 
induce the transcription of a known ERα regulated gene, pS2[9]. The results (Figure 4.2D) 
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demonstrate that, at nanomolar E2 concentrations, the induction of the pS2/TFF1 mRNA was 
nearly equal in the 2 cell lines. This illustrates that the ERα in the KBluc cells is still functional 
and able to regulate an endogenous gene. pS2 is a classical ERα regulated gene containing a near 
consensus ERE.  
The luciferase and pS2 qPCR data demonstrate that the failure of estrogen to stimulate 
proliferation of the T47DKBluc cells in not due to loss or dysfunctional ERα. Therefore, this 
suggests other potential mechanisms, including the disruption of regulation of an endogenous 
ERα regulated gene, as the cause of the defect in proliferation. 
Comparing expression of key E2-ERα-regulated genes in the T47D and T47D-KBluc cells  
Since the KBluc cells contain functional ERα but do not proliferate in response to E2 they 
provide a useful tool in comparison to their wild type counterpart for studying ERα regulated 
genes.  Therefore, we decided to explore a small panel of proposed genes to see if their 
transcription was dysregulated in the KBluc cells.  
 The results (Figure 4.3A-E) show the qPCR data for several known ERα regulated genes 
proposed to be key regulators of E2-ERα signaling.  The panel of genes included FOS, ESR2, 
XBP1, sp-XBP1, and GREB1[10-17]. Interestingly, none of the genes were differentially 
regulated in the 2 cell lines. 
 FOS is a proposed ERa target gene and as shown in Chapter 3 it was not induced by 
picomolar concentrations of E2 indicating that it may not be a key regulator of estrogen induced 
cell proliferation[17]. Similarly we observed that there was no significant difference between 
induction of the FOS gene in the E2 stimulated cell line and the KBluc cells.  
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 GREB1 is an ERa target gene known to be regulated via an upstream Estrogen Response 
Element (ERE) and a key chromatin bound regulatory co-factor in ERa induced transcription. It 
has been shown to be upregulated in breast cancer and an independent prognostic indicator. In 
figure 4.3C we see that GREB1 is not differentially regulated in the two cell lines. Again this 
indicates that this is not one of the possibly misregulated factors important for estrogen induced 
cell proliferation. 
Figure 4.3C shows data for ESR2 the gene which encodes the second isoform of estrogen 
receptor ERb. ERb is expressed in many tissues throughout the body but unlike ERa it has been 
shown to be anti-proliferative in the mammary gland [18-22]. Since ERβ acts as a tumor 
suppressor it should either be overexpressed or remain similarly regulated in the KBluc cells.  
The data shows that ESR2 mRNA is neither increased in response to estrogen or differentially 
regulated in when compared to the wild type cells. 
Figures 4.3D and 4.3E are two genes which form part of the IRE1a arm of the Unfolded 
Protein Response (UPR). The UPR is a critical mediator of translation within cells and has been 
shown to be directly regulated by Estrogen Receptor a to prepare the cell for subsequent 
proliferation[8, 23-25]. XBP1 is regulated by ERa as demonstrated via chromosome wide 
mapping of ER binding sites. Once the UPR is activated, XBP1 is alternatively spliced and 
eventually a protein product called sp-XBP1 is synthesized. sp-XBP1 is a transcription factor and 
it regulates a number of UPR-related genes to stimulate production of proteins that allow for 
correct folding and intracellular transport of proteins. In our system XBP-1 and sp-XBP1 are 
both upregulated in response to E2 in both cell lines.  This critical pathway remains intact at the 
mRNA level and does not behave aberrantly in the KBluc cells as compared to the T47D cells.    
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Here we find that no member of a small panel of genes tested in the T47D KBluc in 
comparison to their wild type counterpart was dysregulated. Since E2 does not stimulate 
proliferation of the KBluc cells, but exhibits normal regulation of these genes, it is possible that 
these genes are not critical for estrogen-induced proliferation. However, it is also possible that 
the tested genes are members of ERa regulated critical pathways which have remained unaltered 
by the process that deprived the KBluc cells of estrogen inducible proliferation.  The panel of 
genes tested is small and represents only a small fraction of the pathways estrogen receptor 
regulates meaning that there remain a number of ERa target gene or genes which may be 
misregulated.  
4.5 Discussion 
Here we describe a novel system consisting of two nearly isogenic cell lines with a 
differential response to E2. The KBluc cells, derived from the wild type T47D cells, do not 
proliferate in response to E2. This deficiency is not due to a lack of ERα or the ability of ERa to 
regulate genes. In fact, in the KBluc cells estrogen induces the transcription of the artificial 
reporter with which they have been stably transfected as well as endogenous ERα regulated 
genes.  
 Since one cell line is derived from the other, the cells are nearly isogenic which provides 
an important advantage over previous experimental models. A key issue in previous work has 
been whether the considerable difference in genetic background between cell lines being 
compared, is itself responsible for substantial differences in gene expression  (4) . Also, under 
our conditions the KBluc cells neither proliferate nor undergo apoptosis in response to estrogen. 
This makes comparisons to the wild-type T47D cells straightforward. 
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 Because the cells do not show any level of proliferation in response to estrogen, we 
expect that they will show clear changes in expression of gene(s) or pathways. We do not know 
whether a single gene or a number of genes is responsible for E2-ERα-stimulated cell 
proliferation. This provides several possible explanations of the data. One possibility is that a 
single gene has been disrupted by the insertion of the luciferase reporter. However, it is equally 
possible that several genes or pathways are aberrantly regulated in the KBluc cells compared to 
the T47D WT cells and that in sum these genes are critical for estrogen dependent growth when 
they are regulated together. It is important to keep in mind that if a gene remains similarly 
regulated between the two cell lines that this simply indicates that it is not the critical estrogen 
dependent growth gene in this cell. Therefore, this does not indicate the relative importance of 
genes concordantly regulated in the two cell lines as they may be critical for estrogen dependent 
cell proliferation but remain functional. In contrast, the assay comparing effects on gene 
expression by pM and nM E2 is a positive assay. Since E2-ERα-stimulates cell proliferation at 
both pM and nM E2, any gene that has lost regulation at pM E2 is not essential for E2-ERα-
stimulated cell proliferation.  
However, this remains a challenging experimental model for a number of technical 
reasons. One is that E2-ERα induction of most test mRNAs is much lower than in MCF-7 cells. 
This will make having an adequate dynamic range, difficult if not impossible on microarrays or 
RNA-Seq. A possibility that cannot be excluded is that the defect in the KBluc cells is not at the 
level of transcriptional regulation by ERa but is due to a mutation in an ERa regulated gene and 
the subsequent loss of downstream effects. Another possibility is that the defect lies at the 
translational level and involves a nonfunctional protein.  
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 Despite the challenges, the system represents the development of an important new 
experimental model that has a very specific phenotype. This phenotype can be characterized and 



























Figure 4.1. T47D-KBluc cells do not proliferate in response to E2. 1,000 cells/well were 
plated in a 96 well plate. The indicated concentrations of E2 in ethanol were added. After 3 days, 
cell number was determined using MTS and a standard curve of T47D-KBluc cells versus 






Figure 4.2. KBluc cells contain functional ER. T47D-KBluc cells were maintained in 5% CD-
FBS for 4 days prior to being plated in 10% CD-CS (A) Schematic diagram of the KBluc 
luciferase reporter system. (B) Relative ERa levels in T47D and T47D-KBluc cells. (C) 
Functional estrogen receptor activates a stably transfected luciferase reporter and is inhibited by 
the competitive ER antagonist ICI 182 780/Faslodex. (D) qRT PCR data from the endogenously 
regulated ERa target gene pS2. Data represents mean fold induction over –E2 sample of 3 






Figure 4.3. Induction of E2-ERα regulated genes does not differ between T47D and T47D KBluc 
cells. Wild type T47D cells and KBluc cells were treated for 4 hours with 10 nM E2, after which 
mRNA was collected and analyzed via qPCR. Data represents mean fold induction over –E2 
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 These studies have identified important new tools for the study of ERa and its central 
role in breast cancer. We demonstrate that what epidemiologic studies have shown regarding 
circulating levels of estrogen and the risk of breast cancer is biologically plausible. Picomolar 
concentrations of E2 can stimulate maximal proliferation of breast cancer cells. We have also 
shown that these concentrations can regulate the transcription of ERa target genes and found that 
at least one purported target gene critical for estrogen induced proliferation is not induced at 
picomolar concentrations. We have also developed a second tool which consists of nearly 
isogenic cell lines where one cell line contains functional ERa but has a deficiency in estrogen 
induced cell proliferation. We demonstrate its potential in identifying genes critical for E2-
stimulated cell proliferation.  
 While we have answered several questions regarding how E2 functions through ER in 
breast cancer cells this also leaves many questions and future directions to pursue. One of the 
largest questions is what are the key E2-ERa regulated genes? To answer this question future 
work employs genome wide approaches including microarrays and RNA-Seq. By using 
escalating concentrations of estrogens one can describe the basal transcriptome of ER up to 
maximal stimulation. Liqun Yu a graduate student in our lab is starting to answer this question 
with RNA sequencing studies. 
 Since only a fraction of the estrogen receptor population is bound with estrogen at 
picomolar concentration it is important to answer what is the signal that targets the initial 
mediators of the genome? ChIP-Seq may provide answers by describing the initial binding sites. 
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This will allow searching for commonalities in the regulated genes and the binding sequences. 
This would provide a powerful tool to allow us to decode how ER regulates the genome. 
The T47D KBluc and T47D cells provide an interesting model where one cell line is 
derived from the other but emerges with a new phenotype; lack of E2 induced cell proliferation. 
Many previously studied systems have introduced exogenous ERa in experimental systems to 
identify novel regulators of ER induced cell proliferation and have managed provided a wealth of 
information. However, these systems have difficulty recapitulating the results in systems with 
endogenous ERa either because the genetic background of the cell lines is so different or 
because the phenotypes are difficult to distinguish. The KBluc cells provide a plus/minus 
phenotype in which the cells do not grow in the presence of estrogen, but their wild type 
counterparts do. These cells provide a new tool to identify critical pathways in E2-ERa induced 
growth by looking at discordantly regulated genes on a global level. Lawrence Wang a graduate 
student in the lab continues to pursue this model and set the system up to look at the entire 
transcriptome. 
In summary, these new tools allow us to explore the ERa transcriptome as it relates to 
breast cancer cells.  Eventually finding the subset of critical downstream targets of ERa will 
allow for the development of better markers to see if endocrine therapies are functioning, a better 
understanding of endocrine resistance mechanisms, and a better idea of how to guide therapeutic 
choice in tumors. Breast cancer affects the lives of nearly a quarter million woman in the US and 
1.5 million worldwide. While a number of therapeutic strategies show important initial success, 
they often lead to resistance. Developing new tools to further our understanding of how estrogen 
receptor works will guide the development of newer, better therapies.  
